February 8, 2016
DURHAM, N.C. – Novan, Inc. today announced that Director Robert A. Ingram has been named Chairman of the Board of Directors of Novan. In addition, Robert Keegan has been appointed to the Board of Directors.
October 7, 2015
DURHAM, N.C. – Novan Therapeutics announced today the addition of two executives from the dermatology industry to the company’s leadership team. Richard Peterson has joined the company as Chief Financial Officer and Brian Johnson as Chief Commercial Officer.
Novan Announces Successful Phase 2b Clinical Trial Results with SB204 for the Treatment of Acne Vulgaris
September 29, 2015
DURHAM, N.C. – Novan Therapeutics announced today positive Phase 2b study results of its topical nitric oxide drug candidate SB204 for the treatment of acne vulgaris, achieving the company’s program goals.
June 10, 2015
DURHAM, N.C. – Novan Therapeutics, a clinical-stage biotechnology company focused on advancing innovation in dermatology via nitric oxide therapies, today announced that following topical application of SB204 there was no measurable systemic exposure in patients with acne vulgaris.